文献速递胸部肿瘤

早期非小细胞肺癌治疗差异的国际注册研究(LUCAEUROPE):欧洲与美国的治疗差异

An International Registry Study of Early-Stage NSCLC treatment variations (LUCAEUROPE) in Europe and the USA highlighting variations.
PubMed 文献 · Eur J Cancer · 2024-07-19

该回顾性队列研究分析2010至2015年六个欧洲国家肿瘤登记库与美国SEER数据库共428,107例早期非小细胞肺癌记录,计算发病率、生存率及年龄标化治疗比例。结果显示各国手术切除率差异显著,美国手术率从67.6%降至59.5%,爱沙尼亚I期患者切除率最高(79.3%)而放疗率最低(7.3%),荷兰各年放疗率最高且2012至2015年手术率最低。结论指出部分欧洲国家和美国切除率下降,各国间差异大。

要点

  • 美国早期NSCLC手术率从67.6%降至59.5%,部分欧洲国家也呈下降趋势
  • 爱沙尼亚I期患者切除率最高(79.3%),放疗率最低(7.3%)
  • 荷兰各年放疗率最高,2012至2015年手术率最低

核心结论

  • 部分欧洲国家和美国的手术切除率下降,且各国间切除率差异显著。
  • 对当前肺癌科学证据和国际指南的解读导致患者治疗存在广泛差异。

研究设计与样本

  • 回顾性队列研究,分析2010至2015年比利时、丹麦、爱沙尼亚、德国、荷兰、斯洛文尼亚六个欧洲国家人群肿瘤登记库及美国SEER数据库数据。
  • 共分析428,107条记录。
  • 计算癌症发病率、生存率及各种治疗使用的年龄标化比例,并用多因素逻辑回归评估切除与人口学和临床参数的关联。

主要发现

  • 爱沙尼亚I期患者手术切除率最高(79.3%),放疗率最低(7.3%)。
  • 荷兰在所有调查年份中放疗率最高,2012至2015年间手术率最低。
  • 美国手术率从67.6%下降至59.5%。
  • 肿瘤分期升高、患者年龄增长、非腺癌的其他肺癌类型以及肿瘤部位跨越多个肺叶时,切除更少进行。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Harmonized European NSCLC incidence, treatment approach, and survival based on national tumor registries are unclear. SUMMARY BACKGROUND DATA: Surgery has the potential to cure NSCLC and significantly prolong survival. This large-scale international study aimed to investigate treatment variations in Europe and the USA, as well as the determinants for its utilization. METHODS: The retrospective cohort study analyzed data from six European national population-based cancer registries (Belgium, Denmark, Estonia, Germany, the Netherlands, and Slovenia) and the US SEER database from 2010-2015. RESULTS: The study computed cancer incidence, survival, and age-standardized proportions of the use of various therapies. Multivariable logistic regression models were used to assess associations between resection and demographic and clinical parameters. A total of 428,107 records were analyzed. Among all countries, Estonia had the highest surgical resection rate (79.3 %) and the lowest radiation rate (7.3 %) for stage I patients. The Netherlands had the highest rate of radiotherapy across all years of investigation and the lowest surgery rate between 2012 and 2015. The primary treatment for early-stage NSCLC showed significant international variation, with the USA having a decrease in surgical rates from 67.6 % to 59.5 %. Resection was less frequently performed as tumor stage increased, patients aged, other lung cancer besides adenocarcinoma was present, and when the tumor site overlapped multiple lobes. CONCLUSIONS: Resection rates have declined in some studied European countries and the USA and resection rates vary substantially among countries. Interpretation of current scientific lung cancer evidence and international guidelines results in wide variations in patient treatment.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Baum P, Cardoso R, Lenzi J, et al. An International Registry Study of Early-Stage NSCLC treatment variations (LUCAEUROPE) in Europe and the USA highlighting variations. Eur J Cancer. 2024. PMID: 39053290. doi:10.1016/j.ejca.2024.114233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。